Field Medical Appoints Dr. Mark A. Turco as New CEO to Drive Growth and Innovation

Field Medical Appoints Dr. Mark A. Turco as New CEO

On March 16, 2026, Field Medical, Inc., a burgeoning medical technology company in the clinical stage, revealed the appointment of Dr. Mark A. Turco as its Chief Executive Officer. Dr. Turco's extensive experience in the cardiovascular field and medical device management positions him as an essential leader to steer Field Medical through its upcoming phases of growth.

Background of Dr. Mark A. Turco

Dr. Turco has dedicated over 30 years to leadership roles within venture-funded cardiovascular startups and major medical device firms. His journey includes steering multiple clinical-stage companies through complex development and strategic exit transactions, all while fostering organizations poised for enduring expansion.

Ben Cannon, a board member of Field Medical and associated with BioStar Capital and Cue Growth, expressed strong confidence in Dr. Turco's capabilities. He stated, “Marks unique background as a cardiologist, clinical investigator, and seasoned medical device executive poorly equips him to guide Field Medical through the next growth phase.” As the company continues to accelerate its clinical programs and enhance its operational capabilities, Dr. Turco's extensive experience in advanced medical technologies will aid in disciplined execution and sustainable long-term value creation.

Prior to his new role, Dr. Turco served as President and CEO of JC Medical, Inc., where he led the development of a specialized transcatheter aortic valve replacement (TAVR) system that was acquired by Edwards Lifesciences in July 2024. His previous leadership experience also includes prominent positions at Medtronic and Covidien, holding significant roles such as Vice President and Chief Medical Officer in Vascular and Neurovascular Technologies, along with the presidency of the Rhode Island Life Science Hub. Dr. Turco, formerly a board-certified interventional cardiologist, brings both clinical insight and operational experience to Field Medical.

Vision for the Future

Dr. Turco shared his enthusiasm about joining Field Medical at this pivotal moment, saying, “The company has built a differentiated PFA platform with the potential to meaningfully address the significant unmet needs of patients suffering from both ventricular arrhythmias and atrial fibrillation.” He looks forward to collaborating closely with the talented team at Field Medical to advance clinical programs consistently and navigate regulatory pathways to achieve operational goals.

About Field Medical, Inc.

Founded in 2022, Field Medical is a clinical-stage medical technology enterprise dedicated to advancing pulsed field ablation (PFA) solutions aimed at addressing complex cardiac arrhythmias. The FieldForce ablation system combines a focused catheter design with proprietary FieldBending™ energy to ensure efficient and precise ablation. This technology aims to enhance outcomes in treating both ventricular and atrial arrhythmias. In 2024, Field Medical received the FDA's Breakthrough Device Designation for its application aimed at addressing ventricular tachycardia, and it participated in the FDA TAP Pilot Program. The VCAS study later published in Circulation in October 2025 further showcases the company’s commitment to groundbreaking research and development.

For additional information about Field Medical, visit www.fieldmedicalinc.com and follow the company on social media platforms including LinkedIn, X, and YouTube.